Patents Expiring in December 2027
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | ||||
Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | ||||
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF ACUTE PAIN | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |